UBXN6: A Potential Drug Target and Biomarker (G80700)

Target Name: UBXN6

NCBI ID: G80700

UBXN6

UBXN6: A Potential Drug Target and Biomarker

Unlike most proteins, UBXN6 is not a natural substance found in the human body. It is a gene that encodes a protein located in the endoplasmic reticulum (ER), which is a structure found within the cells of the body responsible for the production and storage of proteins. UBXN6 is a protein that is expressed in various cell types, including muscle, nerve, and heart cells.

UBXN6 has been shown to play a crucial role in the regulation of a variety of cellular processes. One of its primary functions is to help maintain the stability of the endoplasmic reticulum, which is responsible for the production and storage of proteins. UBXN6 helps to ensure that the ER remains in a stable state, which allows for the proper production and delivery of proteins to their intended destinations.

In addition to its role in maintaining ER stability, UBXN6 has also been shown to play a key role in the regulation of protein function. It helps to ensure that proteins are properly folded and have the correct structure, which is essential for their function. UBXN6 has also been shown to play a role in the regulation of protein degradation, which is the process by which proteins are broken down and removed from the body.

Given its role in so many cellular processes, UBXN6 has potential as a drug target. By targeting UBXN6, researchers may be able to disrupt its function and identify new treatments for a variety of diseases. Additionally, UBXN6 may also be a useful biomarker for certain diseases. For example, high levels of UBXN6 have been shown to be associated with the development of certain neurodegenerative diseases, such as Alzheimer's and Parkinson's.

UBXN6 has also been shown to play a role in the development and progression of certain types of cancer. For example, UBXN6 has been shown to be highly expressed in various types of cancer, including breast, ovarian, and colorectal cancer. This suggests that it may be a useful target for cancer therapies that target this protein.

UBXN6 is also a potential target for neuroprotective treatments. Its role in the regulation of cellular processes makes it a potential target for drugs that are designed to protect against neurodegenerative diseases. Additionally, UBXN6 has also been shown to play a role in the regulation of pain perception, which makes it a potential target for pain-relieving treatments.

In conclusion, UBXN6 is a protein that has the potential to be a drug target and biomarker. Its role in the regulation of cellular processes makes it an attractive target for a variety of therapeutic applications. Further research is needed to fully understand the function and potential of UBXN6, and to determine its utility as a drug target and biomarker.

Protein Name: UBX Domain Protein 6

Functions: May negatively regulate the ATPase activity of VCP, an ATP-driven segregase that associates with different cofactors to control a wide variety of cellular processes (PubMed:26475856). As a cofactor of VCP, it may play a role in the transport of CAV1 to lysosomes for degradation (PubMed:21822278, PubMed:23335559). It may also play a role in endoplasmic reticulum-associated degradation (ERAD) of misfolded proteins (PubMed:19275885). Together with VCP and other cofactors, it may play a role in macroautophagy, regulating for instance the clearance of damaged lysosomes (PubMed:27753622)

The "UBXN6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UBXN6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets